Imprint of parity and age at first pregnancy on the genomic landscape of subsequent breast cancer

Breast Cancer Research

Table 1 Clinicopathological features of nulliparous and parous patients

N	Nulliparous	Parous	P	Early parous	Late parous	P
N	49	264		82	71
Age at diagnosis	54 (30–81)	55 (28–81)	0.796^a	59 (34–81)	49 (28–81)	2.6 × 10^–5a
Menopausal status
Pre	13 (33.3%)	60 (30.3%)	0.85	14 (20.9%)	29 (45.3%)	0.0053
Post	26 (66.7%)	138 (69.7%)	0.85	53 (79.1%)	35 (54.7%)	0.0053
Stage
I	7 (14.9%)	41 (15.9%)	0.019	6 (7.6%)	17 (24.3%)	0.039
II	20 (42.6%)	81 (31.4%)		33 (41.8%)	27 (38.6%)
III	11 (23.4%)	30 (11.6%)		12 (15.2%)	10 (14.3%)
IV	0 (0%)	1 (0.4%)		1 (1.3%)	0 (0%)
Na	9 (19.1%)	105 (40.7%)		27 (34.2%)	16 (22.9%)
pT
Tx	9 (18.4%)	105 (39.8%)	0.0062	27 (32.9%)	16 (22.5%)	0.012
≤ 2 cm	11 (22.4%)	61 (23.1%)		13 (15.9%)	26 (36.6%)
> 2 cm	29 (59.2%)	98 (37.1%)		42 (51.2%)	29 (40.8%)
pN
Nx	11 (22.4%)	112 (42.4%)	0.027	30 (36.6%)	17 (23.9%)	0.2
N0	18 (36.7%)	79 (29.9%)		25 (30.5%)	23 (32.4%)
N1+	20 (40.8%)	73 (27.7%)		27 (32.9%)	31 (43.7%)
Grade
I	6 (14%)	29 (12.7%)	0.93	8 (9.8%)	5 (7%)	0.059
II	17 (39.5%)	86 (37.7%)		25 (30.5%)	35 (49.3%)
III	20 (46.5%)	113 (49.6%)		49 (59.8%)	31 (43.7%)
Subtype by IHC
Lum A-like	22 (44.9%)	106 (40.3%)	0.0013	29 (35.4%)	39 (54.9%)	0.026
Lum B-like	19 (38.8%)	54 (20.5%)		20 (24.4%)	17 (23.9%)
HER2+/HR+	6 (12.2%)	29 (11%)		0 (0%)	0 (0%)
HER2+/HR-	0 (0%)	13 (4.9%)		1 (1.2%)	1 (1.4%)
TNBC	2 (4.1%)	61 (23.2%)		32 (39%)	14 (19.7%)
Histology
Ductal	36 (76.6%)	203 (81.2%)	0.67	71 (88.8%)	49 (71%)	0.01
Lobular	5 (10.6%)	23 (9.2%)		2 (2.5%)	10 (14.5%)
Other	6 (12.8%)	24 (9.6%)		7 (8.8%)	10 (14.5%)

pT pathological tumor size, pN pathological nodal status, HR hormone receptor, P P value derived from χ² test or the Fisher exact test when appropriate
^aExcept continuous variable derived from Mann–Whitney U test

ISSN: 1465-542X